Literature DB >> 20305618

Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.

Laura J Tafe1, Karuna Garg, Ivy Chew, Carmen Tornos, Robert A Soslow.   

Abstract

Carcinomas of the endometrium and ovary with undifferentiated components are uncommon neoplasms that are likely underdiagnosed. They are important to recognize as they have been shown to be clinically aggressive. We identified 32 carcinomas with undifferentiated components as defined by Silva and co-workers, 26 endometrial and 6 of ovarian origin. The patient age ranged from 21 to 76 years (median 55); 40% of patients were <or=50 years of age. Most patients (58% of endometrial and 83% of ovarian carcinomas with undifferentiated components) presented at advanced stages (FIGO III-IV). Pelvic and para-aortic lymph nodes were the most frequent sites of metastases. Twenty tumors, entirely undifferentiated, consisted of sheets of dyshesive, ovoid cells with uniform, large vesicular nuclei, whereas 12 tumors contained combinations of differentiated endometrioid adenocarcinoma with undifferentiated components. Although most undifferentiated tumors had a monotonous cytologic appearance without prominent stroma, six showed focal nuclear pleomorphism and eight cases had variably sized zones of rhabdoid cells in a background of myxoid stroma. The tumors were frequently misdiagnosed; they received a wide range of diagnoses, including FIGO grade 2 or 3 endometrioid carcinoma, carcinosarcoma, high-grade sarcoma including endometrial stromal sarcoma, neuroendocrine carcinoma, lymphoma, granulosa cell tumor and epithelioid sarcoma. Up to 86% of the cases showed focal, but strong keratin and/or epithelial membrane antigen staining, with CK18 being the most frequently positive keratin stain. They were predominantly negative for neuroendocrine markers, smooth muscle markers and estrogen receptor/progesterone receptor. Mismatch repair protein expression by immunohistochemistry was evaluated in 17 cases, and 8 (47%) were abnormal (7 with loss of MLH1/PMS2 and 1 with MSH6 loss). Follow-up was available for 27 patients, although it was very short in many cases, ranging from 0.5 to 89 months (median 9 months). Eleven patients (41%) died of the disease in 0.5-20 months, four are alive with disease and twelve patients have no evidence of disease. Endometrial and ovarian carcinomas with undifferentiated components have a broad histologic differential diagnosis, but they show specific histologic features that should enable accurate diagnosis. These tumors can occur in young women, may be associated with microsatellite instability and behave in a clinically aggressive manner.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305618     DOI: 10.1038/modpathol.2010.41

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

1.  Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Authors:  Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee
Journal:  Histopathology       Date:  2016-07-05       Impact factor: 5.087

2.  Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases.

Authors:  Aatur D Singhi; Raja R Seethala; Katie Nason; Tyler J Foxwell; Robyn L Roche; Kevin M McGrath; Ryan M Levy; James D Luketich; Jon M Davison
Journal:  Hum Pathol       Date:  2014-12-17       Impact factor: 3.466

Review 3.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

Review 4.  [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].

Authors:  A K Höhn; C E Brambs; S Opitz; R Erber; A Hartmann; L-C Horn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 5.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report.

Authors:  Yan Shen; Ying Wang; Yuquan Shi; Jinsong Liu; Yixin Liu
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

7.  Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Authors:  Mackenzie Coatham; Xiaodong Li; Anthony N Karnezis; Lien N Hoang; Basile Tessier-Cloutier; Bo Meng; Robert A Soslow; C Blake Gilks; David G Huntsman; Colin J R Stewart; Lynne M Postovit; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

8.  Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.

Authors:  Juan M Rosa-Rosa; Susanna Leskelä; Eva Cristóbal-Lana; Almudena Santón; Ma Ángeles López-García; Gloria Muñoz; Belen Pérez-Mies; Michele Biscuola; Jaime Prat; Oliva Esther; Robert A Soslow; Xavier Matias-Guiu; Jose Palacios
Journal:  Mod Pathol       Date:  2016-08-05       Impact factor: 7.842

9.  Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.

Authors:  Anthony N Karnezis; Lien N Hoang; Mackenzie Coatham; Sarah Ravn; Noorah Almadani; Basile Tessier-Cloutier; Julie Irving; Bo Meng; Xiaodong Li; Christine Chow; Jessica McAlpine; Kuan-Ting Kuo; Tsui-Lien Mao; Bojana Djordjevic; Robert A Soslow; David G Huntsman; C Blake Gilks; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

10.  Clinicopathological characteristics of anaplastic carcinoma of the pancreas with rhabdoid features.

Authors:  Makoto Sano; Taku Homma; Emiko Hayashi; Hiroko Noda; Yusuke Amano; Ryusuke Tsujimura; Tsutomu Yamada; Brian Quattrochi; Norimichi Nemoto
Journal:  Virchows Arch       Date:  2014-07-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.